prostratin

Subscribe to Selected New Research on prostratin

20 relevant articles (0 outcomes, 1 trials/studies) found for this Bio-Agent

Description: RN given refers to the (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9aalpha))-isomer

Also Known As:

12-deoxyphorbol 13-acetate

Bio-Agent Context: Research Results

Organic Chemicals: 40

Experts

1.	Biancotto, Angélique: 1 article (10/2004)
2.	Hirsch, Ivan: 1 article (10/2004)
3.	Brown, Stephen: 1 article (10/2004)
4.	Grivel, Jean-Charles: 1 article (10/2004)
5.	Vigne, Robert: 1 article (10/2004)
6.	Margolis, Leonid B: 1 article (10/2004)
7.	Bettendroffer, Lise: 1 article (10/2004)
8.	Gondois-Rey, Françoise: 1 article (10/2004)

Related Diseases

1.	Neoplasms (Cancer) 03/15/2008 - "Prostratin is a non-tumor promoting 12-deoxyphorbol monoester capable of up-regulating viral expression from latent provirus and therefore is potentially useful for HIV adjuvant therapy and similar properties might be elicited by related non-tumor promoting phorboids" 11/15/2001 - "Prostratin's lack of tumor promotion, coupled with its ability to block viral spread yet induce latent proviral expression, prompted studies to determine whether this compound could serve as an inductive adjuvant therapy for patients treated with highly active antiretroviral therapy (HAART)" 10/01/2005 - "The lack of tumor promotion of prostratin coupled with its ability to upregulate latent HIV-1 provirus expression and inhibition of viral infection are important features that could be exploited as effective therapy to eliminate latent reservoirs." 06/01/1993 - "The highest dose of prostratin used (2.56 mumol or 1 mg/pretreatment) caused a 96% (23-fold) reduction in the average number of papillomas with a decrease of tumor incidence from 97 to 40%" 01/01/2006 - "Prostratin, a non tumor-promoting phorbol ester, is a candidate for such a strategy" Get all the results and reference details, order at left...
2.	Infection 09/01/2006 - "As has already been shown with prostratin, treatment with I3A resulted in down-regulation of the CD4 receptor and CXCR4 coreceptor suggesting that this was a contributor to the infection inhibition" 09/01/2006 - "Conversely, PKC modulatory compounds inhibited infection of indicator cells (MAGI) with CXCR4-tropic HIV-1 (PMA > I3A > prostratin), and I3A also inhibited infection with CCR5-tropic virus (AD8-1)" 10/01/2004 - "Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue." 08/01/2004 - "Expression of the HIV coreceptors CCR5 and CXCR4 was decreased by prostratin and, concomitantly, prostratin inhibited the infection of PBMCs with R5 and X4 strains" 11/15/2001 - "Prostratin blocks HIV-1 infection relating to down-regulation of CD4 receptor expression" Get all the results and reference details, order at left...
3.	Hyperplasia 10/01/1991 - "Prostratin was more potent for inhibition of ornithine decarboxylase induction (50% inhibitory dose = 25.6 nmol) than it was for hyperplasia: the inhibition was largely attained by the first application, and the recovery from inhibition was slower (8 days)" 10/01/1991 - "Two or more pretreatments with 2.56 mumol (1 mg) prostratin, administered at intervals of 1-4 days, almost completely blocked the hyperplasia induced by phorbol 12-myristate 13-acetate applied 15 min to 6 h after the last pretreatment" 06/01/1993 - "Furthermore, pretreatment with these agents inhibits a range of PMA induced effects (acute and chronic hyperplasia, inflammation, etc.) These observations suggested that prostratin and dPP would function as inhibitors of phorbol ester tumor promotion" 11/01/1992 - "In previous experiments, pretreatment of CD-1 mouse skin with prostratin (12-deoxyphorbol 13-acetate) inhibited hyperplasia, induction of ornithine decarboxylase and edema in response to acute treatment with phorbol 12-myristate 13-acetate (PMA)" 10/01/1991 - "Prostratin, a nonpromoting phorbol ester, inhibits induction by phorbol 12-myristate 13-acetate of ornithine decarboxylase, edema, and hyperplasia in CD-1 mouse skin." Get all the results and reference details, order at left...
4.	HIV Infections (HIV Infection) 10/01/2004 - "Thus, while stimulation with prostratin restricts susceptibility of primary resting CD4(+) T cells to HIV infection at the virus cell-entry level and at the reverse transcription level, it efficiently reactivates HIV-1 from pre- and postintegration latency in resting CD4(+) T cells." 08/01/2002 - "While prostratin alone was not sufficient to allow de novo HIV infection, it efficiently reactivated HIV expression from latently infected cells generated in the SCID-hu mouse" 07/01/2004 - "In addition, prostratin is also able to inhibit de novo HIV infection most probably because it induces down-regulation of HIV receptors from the surface of target cells" 08/01/2002 - "Here we characterized the effects of prostratin, a non-tumor-promoting phorbol ester, on primary human peripheral blood lymphocytes (PBLs) and assessed its ability to reactivate latent HIV infection from thymocytes and PBLs in the SCID-hu (Thy/Liv) model" Get all the results and reference details, order at left...
5.	Edema 10/01/1991 - "Edema was partially inhibited by prostratin (dose giving 50% of maximal inhibition = 512 nmol)" 11/01/1992 - "In previous experiments, pretreatment of CD-1 mouse skin with prostratin (12-deoxyphorbol 13-acetate) inhibited hyperplasia, induction of ornithine decarboxylase and edema in response to acute treatment with phorbol 12-myristate 13-acetate (PMA)" 10/01/1991 - "Prostratin, a nonpromoting phorbol ester, inhibits induction by phorbol 12-myristate 13-acetate of ornithine decarboxylase, edema, and hyperplasia in CD-1 mouse skin." 05/29/1992 - "In skin of CD-1 mice, high doses of prostratin induced ornithine decarboxylase only to 25-30% of the levels induced by typical phorbol esters at doses 1/30 or less than that used for prostratin, produced kinetics of edema formation characteristic of the nonpromoting 12-deoxyphorbol 13-phenylacetate, and failed to induce the acute or chronic hyperplasias typically caused by tumor-promoting phorbols at doses of 1/100 or less than that used for prostratin." Get all the results and reference details, order at left...
12 Diseases and 20 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	phorbol
2.	Protein Kinase C
3.	Ornithine Decarboxylase (Decarboxylase, Ornithine)
4.	HIV Receptors
5.	Phorbol Esters
6.	Proteasome Endopeptidase Complex (Proteasome)
7.	Dextran Sulfate
8.	Phorbols
9.	Oxidoreductases
10.	Hydroxyurea (Hydrea)
15 Drugs and Important Bio-Agents and 17 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
1 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface Subscription

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Searches
2 clicks from Disease to Drug to Evidence
Trial references
All the Positive Outcomes
Drug and Therapy searches
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface Subscription

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>